Clinical Trials Logo

Filter by:
NCT ID: NCT05823454 Recruiting - Clinical trials for Consciousness Disorder

Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness

Start date: September 30, 2022
Phase:
Study type: Observational [Patient Registry]

Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness based on Electroencephalography and Auditory Event-related Potentials

NCT ID: NCT05823441 Completed - Pain Clinical Trials

Effect of Oxytocin Nasal Inhalation on Empathy Analgesia

Start date: June 3, 2023
Phase: Phase 4
Study type: Interventional

This study recruited healthy volunteers and randomly divided them into four groups. They inhaled oxytocin or saline, and watched a pain test video with photos of acquaintances or strangers, respectively, to test whether their feelings of the same thermal pain stimulus had changed.

NCT ID: NCT05823376 Recruiting - Clinical trials for Platelet Recovery After Umbilical Cord Blood Transplantation

Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease

AVA
Start date: May 4, 2023
Phase:
Study type: Observational [Patient Registry]

To evaluate the efficacy and safety of Avatrombopag for platelet recovery after unrelated cord blood transplantation (UCBT) in patients with bone marrow failure disease

NCT ID: NCT05823311 Recruiting - Clinical trials for Advanced Cholangiocarcinoma

Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Start date: October 31, 2023
Phase: Phase 3
Study type: Interventional

Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to undergo surgery. As more effective and novel chemotherapy, targeted therapies, and immunotherapy become available, multiple treatments can be chosen for the patients with advanced CCA. Cytotoxic cell death during tumor chemotherapy triggers antigen release and induces strong anti-tumor effects of T cells. Tyrosine kinase inhibitors (TKI) can reduce the expression of PD-L1 and inhibit Treg cell infiltration, and together with immune checkpoint inhibitors, they can relieve tumor immunosuppressive microenvironment. Therefore, the study aims to investigate the safety and efficacy of Lenvatinib, Tislelizumab combined with Gemcitabine plus Cisplatin (GPLET) in the treatment of advanced cholangiocarcinoma.

NCT ID: NCT05823285 Recruiting - Clinical trials for Advanced Solid Tumors

A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

Start date: March 22, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.

NCT ID: NCT05823272 Recruiting - Gastric Cancer Clinical Trials

ONS in Gastric Cancer After Total Gastrectomy

Start date: March 22, 2024
Phase: N/A
Study type: Interventional

Gastric cancer patients after total gastrectomy will be randomized to oral nutritional supplement group or control group at discharge. Patients will receive 6 months of oral nutritional supplement or normal diet after discharge. The primary and secondary outcomes will be collected.

NCT ID: NCT05823246 Recruiting - Melanoma Clinical Trials

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Start date: April 24, 2023
Phase: Phase 2
Study type: Interventional

This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.

NCT ID: NCT05822869 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Early PP Monitored by EIT in Patients With ARDS

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Acute Respiratory Distress Syndrome (ARDS) is a syndrome characterized by respiratory distress and refractory hypoxemia caused by pulmonary and extra-pulmonary factors. Despite improvements in diagnosis and treatment in recent years, the mortality rate of severe ARDS is still around 40%. The distribution of lung lesions in ARDS patients is significantly gravity-dependent. Even with lung-protective ventilation strategies, tidal volume is concentrated in the ventral lung region, leading to ventilator-associated lung injury. Prone position ventilation can increase ventilation to the dorsal lung tissue and improve the ventilation-perfusion ratio, thus improving oxygenation. During prone position ventilation in ARDS patients, lung-protective ventilation strategies should be maintained, but with different respiratory mechanics from the supine position, requiring adjustment of ventilator parameters. Electrical Impedance Tomography (EIT) technology can be used for bedside monitoring of mechanically ventilated patients, providing real-time feedback on the patient's ventilation status and having great potential for clinical applications. Investigators believes that EIT monitoring during prone position ventilation in ARDS patients can individualize lung-protective ventilation strategies, minimize alveolar overdistension and collapse, improve the weaning success rate of invasive ventilation, and ultimately improve patient prognosis.

NCT ID: NCT05822843 Recruiting - Clinical trials for B-cell Lymphoid Malignancies

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Start date: August 2, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK (pharmacokinetics), and preliminary efficacy and to establish the MTD (maximum tolerated dose), if any, and RP2D (recommended phaseII dose) of ESG206 in adult subjects with B lymphoid malignancies.

NCT ID: NCT05822817 Recruiting - Pituitary Adenoma Clinical Trials

Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery

Start date: May 3, 2023
Phase: Phase 4
Study type: Interventional

Currently, total intravenous anesthesia (TIVA) and inhaled anesthesia are both commonly used for transsphenoidal pituitary adenoma resection. However, optimal choice for anesthesia maintenance in transsphenoidal surgery remains unclear. Previous studies focusing on this question provided fragmentary assessment and controversial results. The goal of this clinical trial is to investigate whether propofol and sevoflurane have different effect on post-anesthetic recovery after transsphenoidal resection of pituitary adenoma.